# F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

> **NCT06206902** · PHASE1 · UNKNOWN · sponsor: **Shanghai Simnova Biotechnology Co.,Ltd.** · enrollment: 55 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** After preconditioning with chemotherapy, F01 will be evaluated.

## Key facts

- **NCT ID:** NCT06206902
- **Lead sponsor:** Shanghai Simnova Biotechnology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04
- **Primary completion:** 2025-01
- **Final completion:** 2025-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06206902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06206902, "F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06206902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*